Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038 ·Status: RECRUITING

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

NCT03460275 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib for Advanced EGFR-positive NSCLC Patients

NCT05037331 ·Status: RECRUITING

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

NCT04563871 ·Status: COMPLETED ·Phase: PHASE2

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683 ·Status: COMPLETED

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

NCT03790397 ·Status: COMPLETED

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 ·Status: RECRUITING ·Phase: PHASE3

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

NCT03434418 ·Status: COMPLETED ·Phase: PHASE2

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

NCT02759835 ·Status: COMPLETED ·Phase: PHASE2

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568 ·Status: RECRUITING ·Phase: PHASE1

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

NCT07213076 ·Status: COMPLETED

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

NCT04606771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

NCT04335292 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03122717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

NCT07322783 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

NCT04974879 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

NCT06530719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 ·Status: RECRUITING ·Phase: PHASE2